MS Speaks

Multiple Sclerosis => TREATMENTS => OCREVUS (ocrelizumab) => Topic started by: agate on May 03, 2017, 10:06:55 am

Title: Ocrevus data update from AAN annual meeting
Post by: agate on May 03, 2017, 10:06:55 am
A summary of information on Ocrevus as presented at the annual AAN conference last month in Boston, from Multiple Sclerosis News Today, April 24, 2017:

https://multiplesclerosisnewstoday.com/2017/04/20/ms-therapy-ocrevus-focus-first-data-update-aan-annual-meeting-fda-approval/?utm_source=Multiple+Sclerosis&utm_campaign=1a4df2d92f-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-1a4df2d92f-71286581 (https://multiplesclerosisnewstoday.com/2017/04/20/ms-therapy-ocrevus-focus-first-data-update-aan-annual-meeting-fda-approval/?utm_source=Multiple+Sclerosis&utm_campaign=1a4df2d92f-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-1a4df2d92f-71286581)